Dall’Agnese, Alessandra
Platt, Jesse M.
Zheng, Ming M.
Friesen, Max http://orcid.org/0000-0002-6699-6619
Dall’Agnese, Giuseppe
Blaise, Alyssa M. http://orcid.org/0000-0001-9958-4488
Spinelli, Jessica B. http://orcid.org/0000-0003-3657-4578
Henninger, Jonathan E. http://orcid.org/0000-0002-9604-2007
Tevonian, Erin N.
Hannett, Nancy M.
Lazaris, Charalampos http://orcid.org/0000-0002-7345-8288
Drescher, Hannah K.
Bartsch, Lea M.
Kilgore, Henry R. http://orcid.org/0000-0003-4851-9656
Jaenisch, Rudolf http://orcid.org/0000-0002-2540-7099
Griffith, Linda G. http://orcid.org/0000-0002-1801-5548
Cisse, Ibrahim I. http://orcid.org/0000-0002-8764-1809
Jeppesen, Jacob F.
Lee, Tong I. http://orcid.org/0000-0003-1847-0898
Young, Richard A. http://orcid.org/0000-0001-8855-8647
Article History
Received: 31 October 2022
Accepted: 17 November 2022
First Online: 6 December 2022
Competing interests
: R.A.Y. is a founder and shareholder of Syros Pharmaceuticals, Camp4 Therapeutics, Omega Therapeutics, and Dewpoint Therapeutics. A.D. is a consultant to Dewpoint Therapeutics. J.F.J. is an employee and shareholder of Novo Nordisk A/S. The remaining authors declare no competing interests. The Whitehead Institute has filed a patent application related to these findings.